PGNY 最新10-Q变化
将 PGNY 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-07 与上一份 10-Q · 2026-05-08
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +14 | −4 | ~29 | 42 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~1 | 3 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 1 |
| 风险因素 | 文字有新增/删除 | 0 | 0 | ~2 | 215 |
| 其他信息 | 文字有新增/删除 | +4 | −2 | 0 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-07
Revenue increased by $22.1 million, or 3%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025. This increase is primarily due to a $19.3 million, or 5%, increase in revenue from our fertility benefits solution and a $2.8 million, or 1%, increase in revenue from our…
Cost of services increased by $4.5 million, or 1%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025. This increase was primarily due to an increase in the medical treatment and pharmacy prescription costs associated with fertility treatments delivered. The increa…
Gross profit increased by $17.6 million, or 11%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025.
Gross margin increased 180 basis points for the six months ended June 30, 2026 compared to the six months ended June 30, 2025, primarily due to ongoing efficiencies realized in the delivery of our care management services as well as a decrease in stock-based compensation expense.
Sales and marketing expense decreased by $1.2 million, or 3%, for the six months ended June 30, 2026 compared to the six months ended June 30, 2025. This decrease was primarily due to a $2.9 million decrease in personnel-related costs, partially offset by a $1.7 million increase in other related sal…
相对上期删除的文字 · 来源:10-Q · 2026-05-08
As of March 31, 2026, we had $131.6 million of cash and cash equivalents and $93.5 million of marketable securities. We have financed our operations primarily through cash generated from the sales of our solutions. Our cash and cash equivalents and working capital are affected by the timing of payme…
On July 1, 2025, we entered into a revolving credit facility (the “Facility”) pursuant to a Credit Agreement (the “Credit Agreement”) with the lenders and issuing banks, party thereto and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swingline lender. The Credit Agreement…
In November 2025, our Board of Directors authorized a share repurchase program of up to $200 million in shares of common stock (the “November 2025 share repurchase program”).
For the three months ended March 31, 2026, we repurchased a total of 5,511,824 shares of common stock under the November 2025 share repurchase program at an average price per share of $21.13 and a total cost of $116.6 million, inclusive of $0.2 million in trading fees. In addition, we recognized $1.…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-07
c.On May 28, 2026, Mark Livingston, our Chief Financial Officer, adopted a trading plan that is intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Livingston’s trading plan is for the sale of up to 28,121 shares of the Company’s common stock in amounts and prices determ…
On June 25, 2026, Allison Swartz, our General Counsel and Secretary, adopted a trading plan that is intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Swartz’s trading plan is for the sale of up to 30,523 shares of the Company’s common stock in amounts and prices determ…
On July 2, 2026, Pete Anevski, our Chief Executive Officer, adopted a trading plan that is intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Anevski’s trading plan is for the sale of up to 1,970,286 shares of the Company’s common stock in amounts and prices determined …
On July 2, 2026, David Schlanger, our Executive Chairman, adopted a trading plan that is intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Schlanger’s trading plan is for the sale of up to 1,300,000 shares of the Company’s common stock in amounts and prices determined …
相对上期删除的文字 · 来源:10-Q · 2026-05-08
c.During the three months ended March 31, 2026, certain of our officers and directors adopted or terminated Rule 10b5-1 trading arrangements as follows:
On January 26, 2026, Peter Anevski, our Chief Executive Officer, terminated the trading plan that was intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act adopted by him on March 31, 2025. The plan provided for the sale of up to 1,244,220 shares of the Company’s common stock i…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议